Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significance mean » significance set (Expand Search), significance test (Expand Search), significance a (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significance mean » significance set (Expand Search), significance test (Expand Search), significance a (Expand Search)
-
3001
Data Sheet 1_The effect of training intervention based on health belief model on self-care behaviors of women with gestational diabetes mellitus.pdf
Published 2025“…The results showed that the mean scores of all structures of the health belief model in the intervention group were significantly different from those obtained after the intervention in this group (p < 0.001). …”
-
3002
Data Sheet 1_Workplace harassment is associated with differences in personality traits, coping strategies and work ability: cross sectional study among healthcare professionals.pdf
Published 2025“…</p>Results<p>Reports of WPH within the past 12 months showed a significantly higher prevalence among women (36.2%, n = 94) compared to men (23.3%, n = 31), p < 0.01. …”
-
3003
Data Sheet 1_The efficacy and safety of panax quinquefolius saponin for heart failure: a systematic review and meta-analysis.pdf
Published 2025“…The results of a meta-analysis under a random-effects model showed that adjuvant PQS therapy significantly increased LVEF (MD = 6.23, 95% CI [4.35, 8.12], P < 0.00001), 6MWTD (MD = 25.26, 95% CI [8.23, 42.30], P = 0.004), and decreased BNP/NT-pro-BNP (MD = −187.94, 95% CI [−267.20, −108.67], P < 0.00001), LVEDV (MD = −22.83, 95% CI [−42.79, −2.87], P = 0.02), LVEDD (MD = −4.76, 95% CI [−5.77, −3.74], P < 0.00001), and LVESV (MD = −11.86, 95% CI [−19.89, −3.83], P = 0.004) in patients with HF.…”
-
3004
CLIC1 upregulation accelerates oxidative stress in oxygen and glucose deprivation/reoxygenation (OGD/R)-treated HT22 cells.
Published 2025“…<p>(a-c) The activities of SOD (a), CAT (b), and GSH-Px (c) were significantly reduced in OGD/R-treated HT22 cells compared to the control group, with the restoration of these antioxidant enzyme activities upon CLIC1 silencing. …”
-
3005
SNAP-25 (1-197) binds to syntaxin-1A, and the interaction is enhanced by Ser187 phosphorylation.
Published 2025“…Syntaxin-1A intensity normalized to SNAP-25 levels in each IP blot was quantified. ns: non-significant; *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. …”
-
3006
Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3007
Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3008
Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3009
Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3010
Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3011
Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3012
Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3013
Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3014
Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3015
Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3016
Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3017
Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3018
Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx
Published 2025“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
-
3019
Evolutionarily conserved and functionally important amino acids in Artemis.
Published 2025“…All flow cytometry data represented the mean ± SD of three biological replicates. <i>P</i> values were analyzed with Student <i>t</i> test. ns, not significant.…”
-
3020
Paiva et al. data
Published 2024“…Pain assessment, clinical evaluation, and the measurement of heart rate (HR) and respiratory rate (RR) were conducted before and during ozone therapy. Ozone therapy significantly affected haemoglobin (F2,20=5.55; P=0.012), mean corpuscular haemoglobin concentrations (MCHC) (F2,20=16.01; P<0.001), and serum aspartate aminotransferase (AST) activity (F2,20=20.49; P<0.001). …”